



Figure S1. Adverse reactions after anti-SARS-CoV-2 vaccination according to age groups. Figure S1A, adverse reactions in the ChAdOx1 #1 group. Figure S1B, adverse reactions in the BNT162b2 #1 group. Figure S1C, adverse reactions in the BNT162b2 #2 group. ChAdOx1 #1, the first dose of ChAdOx1; BNT162b2 #1, the first dose of BNT162b2; BNT162b2 #2, the second dose of BNT162b2. *, trend of a significant decrease in the frequency of adverse reactions across age groups.

Table S1. Side effects and their impacts on the intention to receive the second dose of ChAdOx1 vaccine on various age groups.

Intention to receive the second dose	20–29 year-old			30–39 year-old			40–49 year-old			50–59 year-old		
	Yes (n = 470)	No (n = 143)	p-value	Yes (n = 268)	No (n = 99)	p-value	Yes (n = 286)	No (n = 74)	p-value	Yes (n = 228)	No (n = 37)	p-value
Local reactions	361 (76.8)	124 (86.7)	0.01	197 (73.5)	82 (82.8)	0.07	190 (66.4)	57 (77.0)	0.09	130 (57.0)	23 (62.2)	0.60
Local tenderness	355 (75.5)	121 (84.6)	0.02	196 (73.1)	82 (82.8)	0.06	184 (64.3)	55 (74.3)	0.13	125 (54.6)	22 (59.5)	0.72
Local erythema/heating sense	105 (22.3)	52 (36.4)	<0.01	47 (17.5)	30 (30.3)	0.01	42 (14.7)	28 (37.8)	<0.01	30 (13.2)	9 (24.3)	0.08
Local edema	77 (16.4)	43 (30.1)	<0.01	34 (12.7)	26 (26.3)	<0.01	33 (11.5)	18 (24.3)	0.01	29 (12.7)	6 (16.2)	0.60
Systemic reactions	443 (94.3)	139 (97.2)	0.19	252 (94.0)	96 (97.0)	0.42	247 (86.3)	72 (97.3)	0.01	180 (78.9)	31 (83.8)	1.00
General myalgia	383 (81.5)	129 (90.2)	0.01	209 (78.0)	87 (87.9)	0.04	203 (71.0)	59 (79.7)	0.15	133 (58.3)	27 (73.0)	0.11
Febrile sense	352 (74.9)	113 (79.0)	0.37	165 (61.6)	71 (71.7)	0.09	121 (42.3)	43 (58.1)	0.02	67 (28.4)	15 (40.5)	0.18
Chills	332 (70.6)	117 (81.8)	0.01	175 (65.3)	76 (76.8)	0.04	136 (47.6)	46 (62.2)	0.03	78 (34.2)	22 (59.5)	0.01
Fatigue	283 (60.2)	110 (76.9)	<0.01	177 (66.0)	77 (77.8)	0.03	142 (49.7)	47 (63.5)	0.04	114 (50.0)	19 (51.4)	1.00
Headache	297 (63.2)	117 (81.8)	<0.01	161 (60.1)	77 (77.8)	<0.01	118 (41.3)	48 (64.9)	<0.01	70 (30.7)	22 (59.5)	<0.01
Arthralgia	125 (26.6)	47 (32.9)	0.17	69 (25.7)	33 (33.3)	0.15	88 (30.8)	27 (36.5)	0.40	53 (23.2)	13 (35.1)	0.15
Dizziness	120 (25.5)	48 (33.6)	0.07	47 (17.5)	31 (31.3)	0.01	55 (19.2)	18 (24.3)	0.33	27 (11.8)	9 (24.3)	0.07
Nausea	104 (22.1)	37 (25.8)	0.37	61 (22.8)	22 (22.2)	1.00	37 (12.9)	18 (24.3)	0.02	13 (5.7)	4 (10.8)	0.27
Vomit	22 (4.7)	10 (7.0)	0.29	12 (4.5)	9 (9.1)	0.13	6 (2.1)	4 (5.4)	0.13	3 (1.3)	3 (8.1)	0.04
Pruritus	120 (25.5)	48 (33.6)	0.07	15 (5.6)	8 (8.1)	0.47	19 (6.6)	6 (8.1)	0.61	7 (3.1)	2 (5.4)	0.37
Dyspnea	5 (1.1)	7 (4.9)	0.01	7 (2.8)	5 (5.1)	0.32	2 (0.7)	3 (4.1)	0.06	1 (0.4)	2 (5.4)	0.05
Rash	2 (0.4)	4 (2.8)	0.03	2 (0.7)	2 (2.0)	0.30	0	1 (1.4)	0.21	0	3 (8.1)	0.01

Data are presented as numbers (%) of respondents. Answers of respondents aged ≥ 60 year-old group were not analyzed, because only three (4.1%) respondents refused to receive the second dose of ChAdOx1.